miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Du, Liqin ^a   Subauste, Maria C ^b   DeSevo, Christopher ^b   Zhao, Zhenze ^a   Baker, Michael ^b   Borkowski, Robert ^b   Schageman, Jeoffrey J ^b   Greer, Rachel ^b   Yang, Chin Rang ^c   Suraokar, Milind ^e   Wistuba, Ignacio I ^e   Gazdar, Adi F ^b,c,d   Minna, John D ^b,c,d   Pertsemlidis, Alexander ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MICRORNA; MICRORNA 337 3P; PACLITAXEL; RAP PROTEIN; RAP1A PROTEIN; STAT3 PROTEIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PACLITAXEL; RAP1 GTP-BINDING PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TAXOIDS;

EID: 84862501903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039167     Document Type: Article

References (52)

1. Caesar GJ (50 BC) Commentarii de Bello Gallico (6: 31.
2. Chang AY, Kim K, Glick J Anderson T, Karp D, et al. (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85: 388-394.
3. Murphy WK, Fossella FV, Winn RJ Shin DM, Hynes HE, et al. (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388.
4. Hari M, Loganzo F, Annable T, Tan X, Musto S, et al. (2006) Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 5: 270-278.
5. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, et al. (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305.
6. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, et al. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106.
7. Sangrajrang S, Fellous A, (2000) Taxol resistance. Chemotherapy 46: 327-334.
8. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446: 815-819.
9. Wu L, Fan J, Belasco JG, (2006) MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 103: 4034-4039.
10. Guo H, Ingolia NT, Weissman JS, Bartel DP, (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
11. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, et al. (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722.
12. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
13. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
14. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, et al. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
15. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, et al. (2010) Regression of murine lung tumors by the let-7 microRNA. Oncogene 29: 1580-1587.
16. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
17. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem pp. 32-91.
18. Oie HK, Russell EK, Carney DN, Gazdar AF, (1996) Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem pp. 24-31.
19. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
20. Zhou BB, Peyton M, He B, Liu C, Girard L, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10: 39-50.
21. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, et al. (2009) miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 7: 1234-1243.
22. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
23. Ding LH, Xie Y, Park S, Xiao G, Story MD, (2008) Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology. Nucleic Acids Res 36: e58.
24. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N, (2006) Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 103: 2746-2751.
25. Bussemaker HJ, Li H, Siggia ED, (2001) Regulatory element detection using correlation with expression. Nat Genet 27: 167-171.
26. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
27. Horwitz SB, (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136.
28. Miller ML, Ojima I, (2001) Chemistry and chemical biology of taxane anticancer agents. Chem Rec 1: 195-211.
29. Lynam-Lennon N, Maher SG, Reynolds JV, (2009) The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc 84: 55-71.
30. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
31. Thomas M, Lieberman J, Lal A, (2010) Desperately seeking microRNA targets. Nat Struct Mol Biol 17: 1169-1174.
32. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279.
33. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, et al. (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69: 5876-5884.
34. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, et al. (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70: 2445-2454.
35. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, et al. (2007) Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 133: 352-363.
36. Pensa S, Regis G, Boselli D, Novelli F, Poli V, (2009) STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? In: Stephanou A, editors. editor. JAK-STAT Pathway in Disease. Austin, TX: Landes Bioscience.
37. Kim DJ, Chan KS, Sano S, Digiovanni J, (2007) Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 46: 725-731.
38. Klampfer L, (2006) Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6: 107-121.
39. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, et al. (2009) ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 7: 592-600.
40. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618.
41. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, et al. (2006) Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 172: 245-257.
42. Walker SR, Chaudhury M, Nelson EA, Frank DA, (2010) Microtubule-targeted chemotherapeutic agents inhibit STAT3 signaling. Mol Pharmacol.
43. Fujita H, Fukuhara S, Sakurai A, Yamagishi A, Kamioka Y, et al. (2005) Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes. J Biol Chem 280: 5022-5031.
44. Pizon V, Baldacci G, (2000) Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells. Oncogene 19: 6074-6081.
45. Vossler MR, Yao H, York RD, Pan MG, Rim CS, et al. (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82.
46. Holmfeldt P, Brattsand G, Gullberg M, (2002) MAP4 counteracts microtubule catastrophe promotion but not tubulin-sequestering activity in intact cells. Curr Biol 12: 1034-1039.
47. Hoshi M, Ohta K, Gotoh Y, Mori A, Murofushi H, et al. (1992) Mitogen-activated-protein-kinase-catalyzed phosphorylation of microtubule-associated proteins, microtubule-associated protein 2 and microtubule-associated protein 4, induces an alteration in their function. Eur J Biochem 203: 43-52.
48. Kinbara K, Goldfinger LE, Hansen M, Chou FL, Ginsberg MH, (2003) Ras GTPases: integrins' friends or foes? Nat Rev Mol Cell Biol 4: 767-776.
49. Ahmed AA, Mills AD, Ibrahim AE, Temple J Blenkiron C, et al. (2007) The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12: 514-527.
50. Hattori M, Minato N, (2003) Rap1 GTPase: functions, regulation, and malignancy. J Biochem 134: 479-484.
51. Caron E, (2003) Cellular functions of the Rap1 GTP-binding protein: a pattern emerges. J Cell Sci 116: 435-440.
52. Bromberg J, Darnell JE Jr, (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.